Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2023. Verfasst von Ferda Cevikbas und 3 weiteren Autor:innen. Beteiligte Einrichtung: ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA. Electronic address: ferda.cevikbas@aslanpharma.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Interleukin-13. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Eblasakimab is a first-in-class monoclonal antibody under investigation for the treatment of atopic dermatitis (AD), which targets IL-13Rα1, a subunit of the Type 2 receptor complex. IL-13Rα1 stimulates phosphorylation of signal transducer and activator of transcription 6 (STAT6) to drive inflammation. This brief report investigates the mechanistic basis of eblasakimab and its effects on IL-13Rα1 signaling as part of a phase 1a, open-label, single ascending dose study. Single ascending doses of eblasakimab were administered by intravenous or subcutaneous injection to healthy male volunteers. The impact of eblasakimab on IL-13Rα1 receptor occupancy and STAT6 phosphorylation was assessed in participant blood monocytes. No serious treatment emergent adverse events were reported. Eblasakimab effectively blocked the IL-13Rα1 receptor and inhibited STAT6 phosphorylation with single doses of 3 mg/kg intravenously and 300 mg subcutaneously. Results support further clinical development of eblasakimab as a novel biologic for AD, with potential for 2- to 4-week dosing regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA. Electronic address: ferda.cevikbas@aslanpharma.com.
- ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA.
Zitieren
APA
Cevikbas, F., Ward, A., Firth, C., & Veverka, K. (2023). Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109677
Vancouver
Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109677
BibTeX
@article{Cevikbas2023,
author = {Cevikbas, Ferda and Ward, Alison and Firth, Carl and Veverka, Karen},
title = {Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109677}
}
EUVIMED